{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:17Z","timestamp":1740126437880,"version":"3.37.3"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Materia Medica Holding"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that leads to joint destruction and disability. Despite a significant progress in administration of biological agents for RA patients, there is still a need for improved therapy. Intravenous immunoglobulins (IVIG), a pooled polyspecific immunoglobulin (Ig)G extracted from 5000 to 20 000 healthy subjects, showed beneficial therapeutic effect in patients with immune deficiency, sepsis and autoimmune diseases. The current study aimed to investigate the beneficial effect of treatment with IVIG in established collagen-induced arthritis in DBA\/1j mice. Murine arthritis was induced in DBA\/1j mice. Treatment with IVIG began when the disease was established. The clinical score was followed twice a week until day 48. The mice were bled for plasma and the paws were hematoxylin and eosin (H&amp;E)-stained. Cytokine profile in the plasma was analyzed by Luminex technology and titers of circulating anti-collagen antibodies in the plasma was tested by enzyme-linked immunosorbent assay. Our results show that treatment with IVIG in murine significantly reduced the clinical arthritis score (P\u00a0&amp;lt;\u00a00\u00b7001). Moreover, mode of action showed that IVIG significantly reduced circulating levels of inflammatory cytokines [interferon (IFN)-\u03b3, interleukin (IL)-1\u03b2, IL-17, IL-6, tumor necrosis factor (TNF)-\u03b1, P\u00a0&amp;lt;\u00a00\u00b7001], inhibiting anti-collagen antibodies (P\u00a0&amp;lt;\u00a00\u00b7001) in the plasma of collagen-induced arthritis mice. Importantly, histopathological examination revealed that IVIG treatment prevented the migration of inflammatory immune cells into the cartilage and synovium, reduced the extent of joint damage and preserved joint architecture. Our results proved for the first time the valuable anti-inflammatory treatment of IVIG in experimental RA. We propose IVIG therapy for a subgroup of patients with rheumatologically related diseases.<\/jats:p>","DOI":"10.1111\/cei.13532","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T07:41:32Z","timestamp":1601970092000},"page":"400-408","source":"Crossref","is-referenced-by-count":3,"title":["IVIG ameliorate inflammation in collagen-induced arthritis: projection for IVIG therapy in rheumatoid arthritis"],"prefix":"10.1093","volume":"203","author":[{"given":"G","family":"Halpert","sequence":"first","affiliation":[{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Katz","sequence":"additional","affiliation":[{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Shovman","sequence":"additional","affiliation":[{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Tarasov","sequence":"additional","affiliation":[{"name":"OOO NPF Materia Medica Holding, Moscow, Russia"},{"name":"The Institute of General Pathology and Pathophysiology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K K","family":"Ganina","sequence":"additional","affiliation":[{"name":"OOO NPF Materia Medica Holding, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Petrova","sequence":"additional","affiliation":[{"name":"OOO NPF Materia Medica Holding, Moscow, Russia"},{"name":"The Institute of General Pathology and Pathophysiology, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tocut","sequence":"additional","affiliation":[{"name":"Department of Medicine C, Wolfson Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Volkov","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Sheba Medical Center, Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Barshack","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Sheba Medical Center, Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-6853","authenticated-orcid":false,"given":"M","family":"Blank","sequence":"additional","affiliation":[{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Amital","sequence":"additional","affiliation":[{"name":"Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel"},{"name":"Department of Medicine B, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"2021121023241203800_cei13532-bib-0001","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2021121023241203800_cei13532-bib-0002","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"2021121023241203800_cei13532-bib-0003","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.autrev.2014.08.026","article-title":"Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an \u2018anchor\u2019 drug?","volume":"13","author":"Favalli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021121023241203800_cei13532-bib-0004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2021121023241203800_cei13532-bib-0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2021121023241203800_cei13532-bib-0006","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Among authors: ravetch jv. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"2021121023241203800_cei13532-bib-0007","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0008","first-page":"54","article-title":"The phenomenon of release activity and the hypothesis of \u2018spatial\u2019 homeostas","volume":"44","author":"Epstein","year":"2013","journal-title":"Usp Fiziol Nauk"},{"key":"2021121023241203800_cei13532-bib-0009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4049\/jimmunol.2000098","article-title":"Insights into the mechanism of action of highly diluted biologics","volume":"205","author":"Tarasov","year":"2020","journal-title":"J Immunol"},{"key":"2021121023241203800_cei13532-bib-0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"2021121023241203800_cei13532-bib-0011","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous \u03b3-globulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"volume-title":"Immune Globulin Intravenous (IGIV) Indications","author":"Food and Drug Administration","key":"2021121023241203800_cei13532-bib-0012"},{"key":"2021121023241203800_cei13532-bib-0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","article-title":"Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases","volume":"42","author":"Zandman-Goddard","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021121023241203800_cei13532-bib-0014","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.2174\/138161211798157540","article-title":"Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases","volume":"17","author":"Katz","year":"2011","journal-title":"Curr Pharm Des"},{"key":"2021121023241203800_cei13532-bib-0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10238-005-0079-y","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenousimmunoglobulin","volume":"5","author":"Ephrem","year":"2005","journal-title":"Clin Exp Med"},{"key":"2021121023241203800_cei13532-bib-0016","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrrheum.2011.61","article-title":"Intravenous immunoglobulin therapy in rheumatic diseases","volume":"7","author":"Bayry","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0017","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.autrev.2015.04.003","article-title":"The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis","volume":"14","author":"Katz-Agranov","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2021121023241203800_cei13532-bib-0018","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/keu429","article-title":"Indications for IVIG in rheumatic diseases","volume":"54","author":"Mulhearn","year":"2015","journal-title":"Rheumatology"},{"key":"2021121023241203800_cei13532-bib-0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s100670050158","article-title":"Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin \u2013 a preliminary report","volume":"19","author":"Levy","year":"2000","journal-title":"Clin Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0020","first-page":"404","article-title":"Use of intravenous immunoglobulin in livedo vasculitis","volume":"18","author":"Amital","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0021","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s002960000053","article-title":"Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis","volume":"19","author":"Meissner","year":"2000","journal-title":"Rheumatol Int"},{"key":"2021121023241203800_cei13532-bib-0022","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/B:JOCI.0000019809.55787.ec","article-title":"IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients","volume":"24","author":"Shoenfeld","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021121023241203800_cei13532-bib-0024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000069447","article-title":"Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment","volume":"16","author":"Levy","year":"1998","journal-title":"Nat Immun"},{"key":"2021121023241203800_cei13532-bib-0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/ard.54.5.382","article-title":"Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines","volume":"54","author":"Muscat","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2021121023241203800_cei13532-bib-0026","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.1780351004","article-title":"High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis","volume":"35","author":"Tumiati","year":"1992","journal-title":"Arthritis Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0027","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"2021121023241203800_cei13532-bib-0028","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.it.2008.08.004","article-title":"Modulation of the cellular immune system by intravenous immunoglobulin","volume":"29","author":"Tha-In","year":"2008","journal-title":"Trends Immunol"},{"key":"2021121023241203800_cei13532-bib-0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2021121023241203800_cei13532-bib-0030","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","article-title":"Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021121023241203800_cei13532-bib-0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8802-0_1","article-title":"Collagen-induced arthritis models","volume":"1868","author":"Miyoshi","year":"2018","journal-title":"Methods Mol Biol"},{"key":"2021121023241203800_cei13532-bib-0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cei.12745","article-title":"Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis","volume":"184","author":"Bashi","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2021121023241203800_cei13532-bib-0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200615","article-title":"Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis","volume":"13","author":"Blank","year":"2018","journal-title":"PLOS ONE"},{"key":"2021121023241203800_cei13532-bib-0034","first-page":"1","article-title":"Correct use of repeated measures analysis of variance","volume":"29","author":"Park","year":"2009","journal-title":"Korean J Lab Med"},{"key":"2021121023241203800_cei13532-bib-0035","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.4049\/jimmunol.1402457","article-title":"Immune tolerance induction with multiepitope peptide derive from citrullinated autoantigens attenuates arthritis manifestations in adjuvant arthritis rats","volume":"194","author":"Gertel","year":"2015","journal-title":"J Immunol"},{"key":"2021121023241203800_cei13532-bib-0036","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/cei.12673","article-title":"Immunoglobulin attenuates collagen-induced arthritis in mice","volume":"182","author":"Svetlicky","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021121023241203800_cei13532-bib-0037","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/art.38627","article-title":"Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner","volume":"66","author":"Lee","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0038","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2016.00213","article-title":"K\/BxN serum-transfer arthritis as a model for human inflammatory arthritis","volume":"7","author":"Christensen","year":"2016","journal-title":"Front Immunol"},{"key":"2021121023241203800_cei13532-bib-0039","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12865-019-0328-6","article-title":"Using the K\/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-\u03bcTP-L309C, a recombinant IgG1 Fc hexamer","volume":"20","author":"Lewis","year":"2019","journal-title":"BMC Immunol"},{"key":"2021121023241203800_cei13532-bib-0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1196\/annals.1423.044","article-title":"Itravenous immunoglobulin and cytokines. Focus on tumor necrosis factor family members BAFF and APRIL","volume":"1110","author":"Le Pottier","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"2021121023241203800_cei13532-bib-0041","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/HAB-2001-10201","article-title":"Cytokine levels in various intravenous immunoglobulin (IVIg) preparations","volume":"10","author":"Sherer","year":"2001","journal-title":"Hum Antibodies"},{"key":"2021121023241203800_cei13532-bib-0042","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/stem.5530130303","article-title":"Cytokines and autoantibodies to cytokines","volume":"13","author":"Bendtzen","year":"1995","journal-title":"Stem Cells"},{"key":"2021121023241203800_cei13532-bib-0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"2021121023241203800_cei13532-bib-0044","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"2021121023241203800_cei13532-bib-0045","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2021121023241203800_cei13532-bib-0046","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2021121023241203800_cei13532-bib-0047","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021121023241203800_cei13532-bib-0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4049\/jimmunol.1701093","article-title":"IVIg promote cross-tolerance against inflammatory stimuli in vitro and in vivo","volume":"201","author":"Dom\u00ednguez-Soto","year":"2018","journal-title":"J Immunol"},{"key":"2021121023241203800_cei13532-bib-0049","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1038\/ncomms11205","article-title":"Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis","volume":"7","author":"Ohmi","year":"2016","journal-title":"Nat Commun"},{"key":"2021121023241203800_cei13532-bib-0050","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.4049\/jimmunol.1301611","article-title":"Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils","volume":"192","author":"Campbell","year":"2014","journal-title":"J Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cei.13532","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cei.13532","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/3\/400\/41635301\/cei13532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/203\/3\/400\/41635301\/cei13532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:25:13Z","timestamp":1641054313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/203\/3\/400\/6403222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,10,26]]},"published-print":{"date-parts":[[2021,2,10]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13532","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"type":"print","value":"0009-9104"},{"type":"electronic","value":"1365-2249"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,10,26]]}}}